Speciality: Diabetology
Description:
A warm welcome to all the medical professionals in this interesting session on Experts Perspective on Indian Evidences & Clinical Applications of Vildagliptin 100 mg OD
Vildagliptin, a DPP-4 inhibitor, has gained prominence in the management of type 2 diabetes mellitus (T2DM) in India, particularly with the 100 mg once-daily (OD) regimen. Indian clinical studies have highlighted its efficacy in achieving glycemic control, demonstrating significant reductions in HbA1c levels and postprandial glucose excursions. Experts emphasize the importance of these findings, considering the unique genetic, dietary, and lifestyle factors influencing diabetes management in the Indian population. The 100 mg OD dosing offers convenience and may enhance patient adherence compared to twice-daily regimens.
Indian endocrinologists and diabetologists have reported positive experiences with vildagliptin 100 mg OD in clinical practice, noting its favorable safety profile and tolerability. The incidence of hypoglycemia is notably low, making it a suitable option for elderly patients and those at risk of hypoglycemic events. Additionally, the weight-neutral effect of vildagliptin is a significant advantage, addressing concerns related to weight gain associated with other antidiabetic medications. This aspect is particularly relevant in India, where obesity and overweight are prevalent among T2DM patients.
Therefore, get an overall knowledge of experts perspective on indian evidences & clinical applications of vildagliptin 100 mg OD
See More Webinars @ Hidoc Webinars
1.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
2.
A small rise in cancer was observed following the 1986 Chernobyl accident.
3.
A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.
4.
The hidden costs of cancer for young survivors are derailing their financial futures
5.
Report reveals lung cancer is the leading cause of cancer deaths in Florida
1.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
2.
Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis
3.
Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology
4.
Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review
5.
What You Need To Know About Secondary Polycythemia: Treatment & Symptoms
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
4.
Understanding the causes of anemia in adults beyond nutritional deficiencies
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation